Previous study reported that the conventional TAMs biomarker, CD68+CD163+ could not be fully adequate in ccRCC and the TREM2+ should be one marker to identify TAMs [19]. This evidence concerns the gene TREM2 and nonpapillary renal cell carcinoma.